- Home
- AMSF vs ORKA Comparison
AMSF vs ORKA Comparison
Compare AMSF & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMSF | ORKA |
|---|---|---|
| Founded | 1985 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 519.4M | 7.1B |
| IPO Year | 1996 | 1997 |
Fundamental Metrics
Financial Performance| Metric | AMSF | ORKA |
|---|---|---|
| Price | $24.62 | $90.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $46.33 | ★ $92.50 |
| AVG Volume (30 Days) | 367.3K | ★ 736.2K |
| Earning Date | 04-22-2026 | 05-13-2026 |
| Dividend Yield | ★ 8.61% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $317,252,000.00 | N/A |
| Revenue This Year | $8.45 | N/A |
| Revenue Next Year | $6.03 | N/A |
| P/E Ratio | $20.30 | ★ N/A |
| Revenue Growth | ★ 2.66 | N/A |
| 52 Week Low | $24.11 | $14.89 |
| 52 Week High | $44.66 | $115.52 |
Technical Indicators
Market Signals| Indicator | AMSF | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 47.13 |
| Support Level | N/A | $83.25 |
| Resistance Level | N/A | $97.02 |
| Average True Range (ATR) | 0.00 | 4.32 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 0.00 | 56.57 |
Price Performance
Historical ComparisonAbout AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums. The Company operates as a single reportable segment, Insurance Operations.
About ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.